Enovis (NYSE:ENOV) Insider Oliver Engert Acquires 750 Shares of Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert acquired 750 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The shares were purchased at an average cost of $24.41 per share, with a total value of $18,307.50. Following the transaction, the insider directly owned 45,640 shares of the company’s stock, valued at $1,114,072.40. This trade represents a 1.67% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Oliver Engert also recently made the following trade(s):

• On Monday, March 9th, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were purchased at an average cost of $23.39 per share, with a total value of $23,390.00.
• On Wednesday, March 4th, Oliver Engert purchased 250 shares of Enovis stock. The shares were purchased at an average price of $25.10 per share, for a total transaction of $6,275.00.
• On Tuesday, March 3rd, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was purchased at an average cost of $24.77 per share, for a total transaction of $24,770.00.
• On Friday, February 27th, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were purchased at an average price of $25.50 per share, with a total value of $25,500.00.

Enovis Stock Down 3.2%

NYSE ENOV opened at $23.87 on Wednesday. The business has a fifty day moving average price of $23.97 and a two-hundred day moving average price of $27.93. The stock has a market capitalization of $1.37 billion, a PE ratio of -1.15 and a beta of 1.46. Enovis Corporation has a fifty-two week low of $21.00 and a fifty-two week high of $40.69. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.02 and a quick ratio of 1.04.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The company had revenue of $575.76 million during the quarter, compared to analysts’ expectations of $584.30 million. During the same quarter in the previous year, the firm earned $0.98 EPS. Enovis’s revenue was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities analysts expect that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. UBS Group reissued a “buy” rating and issued a $50.00 target price on shares of Enovis in a report on Monday, January 5th. Canaccord Genuity Group lowered their price objective on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. Needham & Company LLC increased their price objective on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. BTIG Research raised their target price on shares of Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Finally, Evercore reaffirmed an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $47.43.

Institutional Trading of Enovis

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Enovis by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company’s stock valued at $197,945,000 after buying an additional 125,460 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Enovis by 1.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock worth $90,156,000 after buying an additional 51,201 shares during the period. Rubric Capital Management LP bought a new stake in Enovis during the 3rd quarter worth approximately $83,435,000. Hood River Capital Management LLC increased its position in Enovis by 20.3% in the 2nd quarter. Hood River Capital Management LLC now owns 1,735,533 shares of the company’s stock valued at $54,426,000 after acquiring an additional 292,950 shares during the period. Finally, River Road Asset Management LLC increased its position in Enovis by 3.2% in the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after acquiring an additional 46,289 shares during the period. 98.45% of the stock is currently owned by institutional investors.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.